Written by Paul Hsu - NAE Team leader of ACT Genomics
ACT Genomics is the world's leading provider of cancer management solutions and currently has service locations in Taiwan, Singapore, Hong Kong and Japan. Our team of experts specializing in tumor biology, cancer genomics and bioinformatics analysis. Through cutting-edge genetic testing, disease and drug analysis, we provide the best policy for cancer treatment, cancer recurrence and drug resistance monitoring, also provide specific cancer risk assessment and immunotherapy assessment. Through our next-generation sequencing technology and test reporting and integrated service platform, the genetic information of each cancer patient is transformed into an effective action.
Why we changed from other magnetic beads system to iCATCHER?
In the past, when the laboratory people had used other brands of automation equipment for nucleic acid purification, there were always some problems in the experimental process that could not be effectively resolved, such as the poor stability of the extraction result, the reagents taking up a lot of space, the short validity period of reagents, and insufficient nucleic acid purity. The user experience has not reached the expected convenience until we have the opportunity to test iCATCHER automation equipment manufactured by CatchGene. We didn't expect too much but the result really suprised us.
Overall, the operation procedure is pretty simple, the sample is one-on-one matched with the reagent, the reagent has a long storage period, and the nucleic acid purity is high after extraction. The one-way mobile design can reduce the chance of cross-contamination and misplacement of the sample. All aspects meet our needs. So after the test is completed, we switch the original automation platform to iCATCHER.
Compared with other platforms, iCATCHER has the following advantages.